The 36-month beta value for HUMA is also noteworthy at 1.47. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for HUMA is 92.74M, and at present, short sellers hold a 12.31% of that float. The average trading volume of HUMA on September 04, 2024 was 3.41M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
HUMA) stock’s latest price update
Humacyte Inc (NASDAQ: HUMA)’s stock price has dropped by -8.51 in relation to previous closing price of 6.05. Nevertheless, the company has seen a loss of -21.49% in its stock price over the last five trading days. zacks.com reported 2024-08-16 that Humacyte’s (HUMA) Biologic License Application for its ATEV faces a delay as the FDA extends its review timeline, recognizing the product’s potential impact on vascular trauma treatment.
HUMA’s Market Performance
Humacyte Inc (HUMA) has seen a -21.49% fall in stock performance for the week, with a -32.91% decline in the past month and a -24.90% plunge in the past quarter. The volatility ratio for the week is 7.77%, and the volatility levels for the past 30 days are at 9.14% for HUMA. The simple moving average for the last 20 days is -18.99% for HUMA’s stock, with a simple moving average of 18.67% for the last 200 days.
Analysts’ Opinion of HUMA
Many brokerage firms have already submitted their reports for HUMA stocks, with H.C. Wainwright repeating the rating for HUMA by listing it as a “Buy.” The predicted price for HUMA in the upcoming period, according to H.C. Wainwright is $6 based on the research report published on December 11, 2023 of the previous year 2023.
Piper Sandler, on the other hand, stated in their research note that they expect to see HUMA reach a price target of $3.50, previously predicting the price at $2.75. The rating they have provided for HUMA stocks is “Neutral” according to the report published on August 14th, 2023.
Cantor Fitzgerald gave a rating of “Overweight” to HUMA, setting the target price at $6 in the report published on June 22nd of the previous year.
HUMA Trading at -19.14% from the 50-Day Moving Average
After a stumble in the market that brought HUMA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.48% of loss for the given period.
Volatility was left at 9.14%, however, over the last 30 days, the volatility rate increased by 7.77%, as shares sank -29.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +7.06% upper at present.
During the last 5 trading sessions, HUMA fell by -21.49%, which changed the moving average for the period of 200-days by +131.59% in comparison to the 20-day moving average, which settled at $6.72. In addition, Humacyte Inc saw 94.89% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HUMA starting from Niklason Laura E, who purchase 1,222 shares at the price of $6.54 back on Aug 29 ’24. After this action, Niklason Laura E now owns 242,054 shares of Humacyte Inc, valued at $7,998 using the latest closing price.
Dougan Brady W, the Director of Humacyte Inc, purchase 1,222 shares at $6.54 during a trade that took place back on Aug 29 ’24, which means that Dougan Brady W is holding 242,054 shares at $7,998 based on the most recent closing price.
Stock Fundamentals for HUMA
Current profitability levels for the company are sitting at:
- -9.91 for the present operating margin
- 0.23 for the gross margin
The net margin for Humacyte Inc stands at -12.94. The total capital return value is set at -0.89. Equity return is now at value -850.81, with -91.17 for asset returns.
Based on Humacyte Inc (HUMA), the company’s capital structure generated -1.73 points at debt to capital in total, while cash flow to debt ratio is standing at -4.5. The debt to equity ratio resting at -0.63. The interest coverage ratio of the stock is -27.48.
Currently, EBITDA for the company is -92.33 million with net debt to EBITDA at 0.78. When we switch over and look at the enterprise to sales, we see a ratio of 54.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.41.
Conclusion
In summary, Humacyte Inc (HUMA) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
